In This Article:
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on December 18, 2024 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 28, 2024, were voted upon by the shareholders. A total of 5,318,677 common shares of the Company, representing approximately 39.83% of the Company's 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the Meeting.
Shareholders approved the election of four director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. The election of Ms. Janet Grove was withheld and as such, in accordance with the Company's Majority Voting Policy (the "Majority Voting Policy"), Ms. Grove has offered her resignation to the chair of the Board. The Nominating & Governance Committee will, in accordance with the Majority Voting Policy, consider her resignation and make a determination in due course on whether or not it will recommend to the Board to accept Ms. Grove's resignation. A further update will be provided promptly following the Board's determination.
Results of the vote for the election of the board of directors (the "Board") at the Meeting are set out as follows:
| Director | Votes For | Withheld Votes | |||
| Number | Percentage | Number | Percentage | ||
| Eric A. Adams | 1,358,271 | 96.67% | 46,802 | 3.33% | |
| Janet Grove | 621,901 | 44.26% | 783,172 | 55.74% | |
| Andrew Hull | 1,358,517 | 96.69% | 46,556 | 3.31% | |
| Nicole Lemerond | 1,358,261 | 96.67% | 46,812 | 3.33% | |
| Bryan Baldasare | 1,358,152 | 96.66% | 46,921 | 3.34% | |
Shareholders also voted to approve Marcum LLP (now doing business as CBIZ LLP) as the Company's auditors for the following year. No other matters were brought before the meeting.
InMed filed a report of voting results on SEDAR at www.sedarplus.ca on December 18, 2024.
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.